Daratumumab, a biological drug that targets CD38, was recently licensed for the plasma cell malignancy, myeloma.11 12 This human anti-CD38 monoclonal antibody has the potential to deplete plasma cells and therefore produce a rapid reduction in TRAb levels, which may alter the natural history of severe Graves’ disease. This evidence concerns the gene CD38 and plasma cell myeloma.